

10 June 2001
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
HERSCOVICI ET AL.

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Serial No.: 09/857,008

Filed: **September 12, 1999**

Title: **Novel Nucleic Acid Transferring Agents,
Compositions Containing them and Uses**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
~~Express Mail~~ in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit

Signature

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686
Attorney Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626